COVID-19 diagnostics intended for home use and those that allow for processing large sample batches are being prioritized by the US Food and Drug Administration review staff, according to an agency official.
Timothy Stenzel, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health, said during a 10 June webinar that reviewers in the virology department have been seeing about 60 times more emergency use authorization (EUA) submissions than
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?